Heroin, also known as diacetylmorphine, is derived from the opium poppy plant. Bayer Pharmaceuticals developed the diacetylmorphine molecule in 1898 as an antitussive. Professionals initially touted morphine as a substitute with less addiction potential. Heroin currently has no FDA-approved indications for use. Heroin is a Schedule I drug under the Controlled Substances Act of 1970, with no approved medical use in the United States. The United Kingdom allows the use of heroin, known under the generic name of diamorphine, for diverse analgesic indications such as postoperative pain, chronic pain, palliative care, and even post caesarean section.
Heroin's chief place in American healthcare remains problematic. As an illicit opioid, people have abused heroin for decades. In the 21st century, the use of heroin has caused a surge in both dependence and overdose deaths. Though people in other countries use heroin, in the United States, it has no recognized therapeutic role in managing opioid addiction.
Heroin is synthetically derived from the morphine alkaloid in opium and is approximately twice as potent as morphine. Heroin acts agonistically on central nervous system (CNS) opioid receptors mu, kappa, and delta. Mu receptor effects account for both the analgesic effects (Mu1) and the respiratory depression and euphoria (Mu2). Activation of Mu2 receptors also cause miosis, reduced gastrointestinal (GI) motility, and physiologic dependence. Kappa receptor activation causes some degree of analgesia as well. Delta receptors are more involved in spinal analgesia phenomena.
Heroin is metabolized in the CNS to monoacetylmorphine, which is a more potent mu-receptor agonist than morphine. Peripheral tissues metabolize heroin to 6-monoacetylmorphine and then morphine. Many state toxicology labs use the 6-monoacetylmorphine to determine which overdose deaths were due to heroin.
When taken orally, heroin undergoes first pass metabolism to morphine, via deacetylation. Therefore, unlike intravenous administration, oral ingestion does not cause a rapid onset of effects and is less desirable to users. 6-monoacetylmorphine and morphine activate opioid receptors.
As mentioned above, practitioners in the United States do not administer heroin in any sanctioned healthcare setting. Illicitly, people abuse heroin via subcutaneous, intranasal, intramuscular, intravenous methods. Heroin is highly lipophilic and therefore rapidly crosses the blood-brain barrier. All routes of administration lead to rapid absorption of heroin. Peak serum levels in each of these routes are as follows: five to ten minutes subcutaneously, three to five minutes intranasally and intramuscularly, and less than one minute intravenously.
Once absorbed into the serum, heroin reaches the brain in 15 to 20 seconds. While less than 5% of intravenous morphine reaches the brain, 68% of intravenous heroin makes contact with receptors in the brain. This rapid effect gives the user a rush that typically leads to continued use with hopes of achieving that same first experience of euphoria.
The intended effects of heroin abuse are those classically associated with any opioid effects. These are analgesia, euphoria, and often alleviation of opioid withdrawal symptoms. All other effects of heroin could be considered adverse. Respiratory depression is likely the most concerning adverse effect, leading to death in an increasing number of abusers. The very strong physiologic dependence also represents a major concern in those who abuse heroin.
Heroin reliably causes decreased GI motility, which commonly leads to constipation. This decreased motility can be problematic enough for users that they may require medical attention to relieve constipation. Miosis represents a minimal concern to healthcare providers or those abusing the drug, though this effect can have diagnostic value.
Some practitioners have described severe, life-threatening pulmonary edema in patients who abuse or overdose on heroin. This edema is noncardiogenic and likely relates to increased pulmonary vascular permeability.
Practitioners have also attributed cases of compartment syndrome to heroin use.
Because the FDA recognizes no medical use for heroin, it has not specified any contraindications. In countries where people use the drug for medical purposes, hypersensitivity and potential for abuse or dependence could be perceived contraindications.
Canada lists heroin as a Schedule I drug in the Controlled Drugs and Substances Act. Various countries have enforced different levels of criminal regulation related to heroin.
Again, with no approved use for heroin, no therapeutic index exists. However, pharmacodynamically, heroin could be considered to have a very narrow therapeutic window. Due to variations in potency and concentration, users are not aware of the true amount of the active drug in any given sample. Therefore the same apparent dose that causes euphoria one day could very well lead to an overdose the next.
Drug levels are not typically used, though toxicology assessments post-mortem may quantify a number of metabolites .
Professionals thoroughly describe heroin toxicity in the literature and popular media. With the high rate of prescription opioid addiction (see opioid use disorder), and the lower cost of heroin, many individuals have developed heroin dependence. As discussed above, heroin (especially if administered intravenously) is very likely to cause an overdose and death due to respiratory depression. From 2002 through 2013, heroin overdoses went from 0.7 deaths per 100,000 to 2.7. In 2013, roughly 517,000 people reported heroin use in the past year, 1.5 times the amount in 2007. State and federal legislation are implementing diverse methods to curb this epidemic of heroin overdose deaths. The many infectious and economic effects of heroin dependence add to the risk of death.
The antidote for heroin overdose or poisoning is naloxone. Naloxone binds with high affinity to the Mu receptors in the CNS. Administration of naloxone is an inverse agonist and if given in high enough dose will induce withdrawal in an opioid-dependent patient. Naloxone is also believed to block binding of endogenous opioids. Practitioners can administer naloxone intravenously, intramuscularly, and increasingly intranasally. Many first responders now carry intranasal naloxone kits to reverse heroin or opioid overdose in field settings.
Naltrexone, a long acting opioid antagonist, is available both orally and as a long acting intramuscular injection. The risk of precipitating an prolonged withdrawal syndrome, however, prohibits the use as an antidote for initial reversal. These long acting opioid antagonists are being used in medication assisted treatment for patients with opioid use disorder.
Medication Assisted Treatment represents an effective option for treatment of heroin dependence and opioid use disorder in general. Buprenorphine and methadone are the chief agents used, with buprenorphine being more safe and effective. Buprenorphine also has a higher affinity for the mu opioid receptors than does heroin .
|||Sneader W, The discovery of heroin. Lancet (London, England). 1998 Nov 21; [PubMed PMID: 9853457]|
|||Rosen D,Hunsaker A,Albert SM,Cornelius JR,Reynolds CF 3rd, Characteristics and consequences of heroin use among older adults in the United States: a review of the literature, treatment implications, and recommendations for further research. Addictive behaviors. 2011 Apr; [PubMed PMID: 21237575]|
|||Metrebian N,Mott J,Carnwath Z,Carnwath T,Stimson GV,Sell L, Pathways into receiving a prescription for diamorphine (heroin) for the treatment of opiate dependence in the United kingdom. European addiction research. 2007; [PubMed PMID: 17570910]|
|||Cicero TJ,Ellis MS,Surratt HL,Kurtz SP, The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA psychiatry. 2014 Jul 1; [PubMed PMID: 24871348]|
|||The societal cost of heroin use disorder in the United States., Jiang R,Lee I,Lee TA,Pickard AS,, PloS one, 2017 [PubMed PMID: 28557994]|
|||Goldstein A, Heroin addiction: neurobiology, pharmacology, and policy. Journal of psychoactive drugs. 1991 Apr-Jun; [PubMed PMID: 1662715]|
|||Maas A,Madea B,Hess C, Confirmation of recent heroin abuse: Accepting the challenge. Drug testing and analysis. 2018 Jan; [PubMed PMID: 28681463]|
|||Dinis-Oliveira RJ, Metabolism and metabolomics of opiates: A long way of forensic implications to unravel. Journal of forensic and legal medicine. 2019 Feb [PubMed PMID: 30621882]|
|||Gottås A,Arnestad M,Halvorsen PS,Bachs LC,Høiseth G, Pharmacokinetics of heroin and its metabolites in vitreous humor and blood in a living pig model. Forensic toxicology. 2016 [PubMed PMID: 27660664]|
|||Pasternak GW, Mu Opioid Pharmacology: 40 Years to the Promised Land. Advances in pharmacology (San Diego, Calif.). 2018 [PubMed PMID: 29413524]|
|||[PubMed PMID: 29171813]|
|||[PubMed PMID: 28958275]|
|||Prangnell A,Fairgrieve C,Nosova E,DeBeck K,Milloy MJ,Hayashi K, High Prevalence of Self-Reported Exposure to Adulterated Drugs Among People Who Experienced an Opioid Overdose in Canada: A Cohort Study. Substance use [PubMed PMID: 30663484]|
|||It's not just heroin anymore., Arens A,Olives T,Laes J,Cole J,, Clinical toxicology (Philadelphia, Pa.), 2017 Jul [PubMed PMID: 28440696]|
|||Faryar KA,Freeman CL,Persaud AK,Furmanek SP,Guinn BE,Mattingly WA,Wiemken TL,Buckner KA,Huecker MR, The Effects of Kentucky's Comprehensive Opioid Legislation on Patients Presenting with Prescription Opioid or Heroin Abuse to One Urban Emergency Department. The Journal of emergency medicine. 2017 Dec; [PubMed PMID: 29102093]|
|||Hedegaard H,Chen LH,Warner M, Drug-poisoning deaths involving heroin: United States, 2000-2013. NCHS data brief. 2015 Mar; [PubMed PMID: 25932890]|
|||Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013., Jones CM,Logan J,Gladden RM,Bohm MK,, MMWR. Morbidity and mortality weekly report, 2015 Jul 10 [PubMed PMID: 26158353]|
|||Skolnick P, On the front lines of the opioid epidemic: Rescue by naloxone. European journal of pharmacology. 2018 Sep 15; [PubMed PMID: 30092179]|
|||Bradley ES,Liss D,Carriero SP,Brush DE,Babu K, Potential uses of naltrexone in emergency department patients with opioid use disorder. Clinical toxicology (Philadelphia, Pa.). 2019 Mar 4; [PubMed PMID: 30831039]|
|||[PubMed PMID: 28194688]|